155 related articles for article (PubMed ID: 1310099)
41. A lambda 1 transgene under the control of a heavy chain promoter and enhancer does not undergo somatic hypermutation.
Hengstschläger M; Williams M; Maizels N
Eur J Immunol; 1994 Jul; 24(7):1649-56. PubMed ID: 8026525
[TBL] [Abstract][Full Text] [Related]
42. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
43. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
44. Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis.
Hueber AO; Bösser S; Zörnig M
Int J Cancer; 2004 Nov; 112(3):536-40. PubMed ID: 15382083
[TBL] [Abstract][Full Text] [Related]
45. Driven by the same Ig enhancer and SV40 T promoter ras induced lung adenomatous tumors, myc induced pre-B cell lymphomas and SV40 large T gene a variety of tumors in transgenic mice.
Suda Y; Aizawa S; Hirai S; Inoue T; Furuta Y; Suzuki M; Hirohashi S; Ikawa Y
EMBO J; 1987 Dec; 6(13):4055-65. PubMed ID: 2832150
[TBL] [Abstract][Full Text] [Related]
46. Allele-specific loss or imbalance of chromosomes 9, 15, and 16 in B-cell tumors from interspecific F1 hybrid mice carrying Emu-c-myc or N-myc transgenes.
Linardopoulos S; Silva S; Klein G; Balmain A
Int J Cancer; 2000 Dec; 88(6):920-7. PubMed ID: 11093815
[TBL] [Abstract][Full Text] [Related]
47. Cell populations during tumorigenesis in Eu-myc transgenic mice.
Sidman CL; Shaffer DJ; Jacobsen K; Vargas SR; Osmond DG
Leukemia; 1993 Jun; 7(6):887-95. PubMed ID: 8501983
[TBL] [Abstract][Full Text] [Related]
48. Use of E mu-PIM-1 transgenic mice short-term in vivo carcinogenicity testing: lymphoma induction by benzo[a]pyrene, but not by TPA.
Kroese ED; Dortant PM; van Steeg H; van Oostrom CT; van der Houven van Oordt CW; van Kranen HJ; de Vries A; Wester PW; van Kreijl CF
Carcinogenesis; 1997 May; 18(5):975-80. PubMed ID: 9163683
[TBL] [Abstract][Full Text] [Related]
49. Transgenic mice with mu and kappa genes encoding antiphosphorylcholine antibodies.
Storb U; Pinkert C; Arp B; Engler P; Gollahon K; Manz J; Brady W; Brinster RL
J Exp Med; 1986 Aug; 164(2):627-41. PubMed ID: 2425036
[TBL] [Abstract][Full Text] [Related]
50. L-myc and N-myc in hematopoietic malignancies.
Hirvonen H; Hukkanen V; Salmi TT; Pelliniemi TT; Alitalo R
Leuk Lymphoma; 1993 Oct; 11(3-4):197-205. PubMed ID: 8260894
[TBL] [Abstract][Full Text] [Related]
51. Lymphoid and non-lymphoid tumors in E kappa-myc transgenic rabbits.
Sethupathi P; Spieker-Polet H; Polet H; Yam PC; Tunyaplin C; Knight KL
Leukemia; 1994 Dec; 8(12):2144-55. PubMed ID: 7808003
[TBL] [Abstract][Full Text] [Related]
52. Ig heavy chain protein controls B cell development by regulating germ-line transcription and retargeting V(D)J recombination.
Schlissel MS; Morrow T
J Immunol; 1994 Aug; 153(4):1645-57. PubMed ID: 8046237
[TBL] [Abstract][Full Text] [Related]
53. Heterogeneity of B-lymphoid tumors in E mu-myc transgenic mice.
Prasad VS; Temple MJ; Davisson MT; Akeson EC; Sidman CL
Cytometry; 1996 Feb; 23(2):131-9. PubMed ID: 8742172
[TBL] [Abstract][Full Text] [Related]
54. Hemopoietic neoplasms in lethally irradiated mice repopulated with bone marrow cells carrying the human c-myc oncogene: a repopulation assay.
Hirabayashi Y; Inoue T; Suda Y; Aizawa S; Ikawa Y; Kanisawa M
Exp Hematol; 1992 Feb; 20(2):167-72. PubMed ID: 1544384
[TBL] [Abstract][Full Text] [Related]
55. Preferential development of pre-B lymphomas with drastically down-regulated N-myc in the E mu-ret transgenic mice.
Iwamoto T; Pu M; Ito M; Takahashi M; Isobe K; Nagase F; Kawashima K; Ichihara M; Nakashima I
Eur J Immunol; 1991 Aug; 21(8):1809-14. PubMed ID: 1868872
[TBL] [Abstract][Full Text] [Related]
56. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss.
Blyth K; Terry A; O'Hara M; Baxter EW; Campbell M; Stewart M; Donehower LA; Onions DE; Neil JC; Cameron ER
Oncogene; 1995 May; 10(9):1717-23. PubMed ID: 7753548
[TBL] [Abstract][Full Text] [Related]
57. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
Dyall-Smith D; Cory S
Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
[TBL] [Abstract][Full Text] [Related]
58. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice.
Park SS; Shaffer AL; Kim JS; duBois W; Potter M; Staudt LM; Janz S
Cancer Res; 2005 Sep; 65(17):7644-52. PubMed ID: 16140930
[TBL] [Abstract][Full Text] [Related]
59. Moloney virus induction of T-cell lymphomas in a plasmacytomagenic strain of E mu-v-abl transgenic mice.
Haupt Y; Harris AW; Adams JM
Int J Cancer; 1993 Oct; 55(4):623-9. PubMed ID: 8406991
[TBL] [Abstract][Full Text] [Related]
60. Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc.
Karsunky H; Geisen C; Schmidt T; Haas K; Zevnik B; Gau E; Möröy T
Oncogene; 1999 Dec; 18(54):7816-24. PubMed ID: 10618723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
